Category Archives: Stem Cell Clinic

United Veterinary Center Norwalk Offers Stem Cell Therapy to Treat … – MilTech

Norwalk, CT United Veterinary Center Norwalk humbly announces that their veterinary clinic now offers stem cell therapy to treat pets without any invasive therapy. This Norwalk veterinarian is the first among any other veterinary clinic to offer such a groundbreaking procedure. With its release, pet lovers and owners who have pets with serious medical conditions can now avail of this procedure at their clinic. The research for the stem cell therapy was backed by the Kansas State University independent of MediVet Biologics based on the work of Dr. David A. Upchurch and Dr. Mark L. Weiss.

In a statement by Dr. Gil Stanzione, a CT veterinarian and one of their senior vets, he stated that Our team of medical experts is equipped with up to date advances in veterinary research and technology. Hereat the Center, our experienced Norwalk vet understands the value of your pet to your family. By adopting the stem cell therapy, the clinic stands firm to their word to provide their clients with the newest and latest procedures available. He also added that We are devoted to giving your pets the excellent healthcare and medical services they truly deserve. With the latest technology and state-of-the-art veterinary equipment available in our medical center in Norwalk, Connecticut, your beloved pets are safe in our hands.

The stem cell therapy this Norwalk veterinarian offers is called the ActiStem. The procedure involves an incorporation of a concentration of regenerative stem cells and other repair cells to the damaged portion of the pets body. With the procedure now available at their disposal, the fear of losing a precious member of the family will slowly decrease knowing that there is a veterinary clinic available to treat their pets. Pet owners can rest assured that the procedure their pet will undergo will have no adverse side effects and without the need of intensive therapy.

United Veterinary Center is a veterinary clinic that offers a variety of services and treatments for family pets. The services they offer include administration of vaccinations, wellness programs for pets to keep them healthy, dental care, as well as surgeries and microchip installations. The facilities and services that this Norwalk, CT vet offers are specially designed to take care of your pets. Their clinic can handle medical conditions that may require hospitalization or intensive care for their clients beloved pet.

To avail of their stem cell therapy, United Veterinary Center Norwalk is located at 48 Westport Avenue #2 Norwalk, CT 06851. To know more about the services and the procedures this Norwalk CT veterinarian offers, please visit their website at http://unitedveterinarycenter.com/, or call them at (203) 349-6895.

They can also be contacted via email at info@unitedveterinarycenter.com

Media Contact Company Name: United Veterinary Center Norwalk Contact Person: Dr. Gil Stanzione Email: info@unitedveterinarycenter.com Phone: (203) 349-6895 Address:48 Westport Avenue #2 City: Norwalk State: Connecticut Country: United States Website: http://unitedveterinarycenter.com/

Continue reading here:
United Veterinary Center Norwalk Offers Stem Cell Therapy to Treat ... - MilTech

SpaceX to launch heart, bone health experiments to space station – CU Boulder Today

Editors note: The SpaceX Falcon 9 rocket scheduled to launch today from Florida was delayed due to weather conditions. The launch has been rescheduled for Saturday, June 3.

A SpaceX rocket wasslated to launch two University of Colorado Boulder-built payloads to the International Space Station (ISS) from Florida on Thursday, including oneto look at changes in cardiovascular stem cells in microgravity that may someday help combat heart disease on Earth.

The Dragon spacecraft

The second payload will be used for rodent studies testing a novel treatment for bone loss in space, which has been documented in both astronauts and mice. The two payloads were developed by BioServe Space Technologies, a research center within the Ann and H.J Smead Department of Aerospace Engineering,

We have a solid relationship with SpaceX and NASA that allows us to regularly fly our flight hardware to the International Space Station, said BioServe Director Louis Stodieck. The low gravity of space provides a unique environment for biomedical experiments that cannot be reproduced on Earth, and our faculty, staff and students are very experienced in designing and building custom payloads for our academic, commercial and government partners.

The experiments will be launched on a SpaceX Falcon 9 rocket from Cape Canaveral, Florida, and carried to the ISS on the companys Dragon spacecraft. The SpaceX-CRS-11 mission launching Thursday marks BioServes 55th mission to space.

The cardiovascular cell experiments, designed by Associate Professor Mary Kearns-Jonker of the Loma Linda University School of Medicine in Loma Linda, California, will investigate how low gravity affects stem cells, including physical and molecular changes. While spaceflight is known to affect cardiac cell structure and function, the biological basis for such impacts is not clearly understood, said BioServe Associate director Stefanie Countryman.

As part of the study, the researchers will be comparing changes in heart muscle stem cells in space with similar cells simultaneously cultured on Earth, said Countryman. Researchers are hopeful the findings could help lead to stem cell therapies to repair damaged cardiac tissue. The findings also could confirm suspicions by scientists that microgravity speeds up the aging process, Countryman said.

For the heart cell experiments, BioServe is providing high-tech, cell-culture hardware known as BioCells that will be loaded into shoebox-sized habitats on ISS. The experiments will be housed in BioServes Space Automated Bioproduct Lab (SABL), a newly updated smart incubator that will reduce the time astronauts spend manipulating the experiments.

The second experiment, created by Dr. Chia Soo of the UCLA School of Medicine, will test a new drug designed to not only block loss of bone but also to rebuild it.

The mice will ride in a NASA habitat designed for spaceflight to the ISS. Once on board, some mice will undergo injections with the new drug while others will be given a placebo. At the end of the experiments half of the mice will be returned to Earth in SpaceXs Dragon spacecraft and transported to UCLA for further study, said Stodieck, a scientific co-investigator on the experiment.

BioServes Space Automated Byproduct Lab

In addition to the two science experiments, BioServe is launching its third SABL unit to the ISS. Two SABL units are currently onboard ISS supporting multiple research experiments, including three previous stem cell experiments conducted by BioServe in collaboration with Stanford University, the Mayo Clinic and the University of Minnesota.

The addition of the third SABL unit will expand BioServes capabilities in an era of high-volume science on board the ISS, said Countryman.

BioServe researchers and students have flown hardware and experiments on missions aboard NASA space shuttles, the ISS and on Russian and Japanese government cargo rockets. BioServe previously has flown payloads on commercial cargo rockets developed by both SpaceX, headquartered in Hawthorne, California, and Orbital ATK, Inc. headquartered in Dulles, Virginia.

Since it was founded by NASA in 1987, BioServe has partnered with more than 100 companies and performed dozens of NASA-sponsored investigations. Itspartners include large and small pharmaceutical and biotechnology companies, universities and NASA-funded researchers, and investigations sponsored by the Center for the Advancement of Science in Space, which manages the ISS U.S. National Laboratory. CU-Boulder students are involved in all aspects of BioServe research efforts, said Stodieck.

Read the rest here:
SpaceX to launch heart, bone health experiments to space station - CU Boulder Today

Sickle cell cure is real, as this Kansas patient proves – Kansas City Star


Kansas City Star
Sickle cell cure is real, as this Kansas patient proves
Kansas City Star
Though pioneered three decades ago as the first sickle cell cure, bone marrow stem cell transplants remain underused especially for adult patients because of the risks involved, a lack of public awareness and a shortage of bone marrow donors for ...

Read this article:
Sickle cell cure is real, as this Kansas patient proves - Kansas City Star

US Stem Cell Inc (OTCMKTS:USRM) HEFFX Highlights – Live Trading News

US Stem Cell Inc (OTCMKTS:USRM) HEFFX Highlights

U.S. Stem Cell, Inc., formerly Bioheart, Inc., is a biotechnology company. The Company is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its MyoCell is a clinical therapy designed to populate regions of scar tissue within a patients heart with autologous muscle cells, or cells from a patients body, for the purpose of improving cardiac function in chronic heart failure patients. Its AdipoCell is a cell therapy with multiple possible treatment applications using autologous adipose cells. Its business includes the development of cell therapy products, as well as physician and patient-based regenerative medicine/cell therapy training services, and the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. It operates through divisions, including US Stem Cell Training, Vetbiologics and US Stem Cell Clinic.

Overall, the bias in prices is: Upwards.

Short term: Prices are moving.

Intermediate term: Prices are trending.

Note: this chart shows extraordinary price action to the upside.

The projected upper bound is: 0.16.

The projected lower bound is: 0.09.

The projected closing price is: 0.12.

U S STEM CELL closed up 0.018 at 0.123. Volume was 48% below average (neutral) and Bollinger Bands were 11% narrower than normal.

Open High Low Close Volume 0.107 0.130 0.107 0.123 11,054,231

Technical Outlook Short Term: Neutral Intermediate Term: Bearish Long Term: Bullish

Moving Averages: 10-period 50-period 200-period Close: 0.10 0.09 0.03 Volatility: 148 304 409 Volume: 5,141,926 18,776,992 10,868,120

Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.

Summary U S STEM CELL is currently 339.5% above its 200-period moving average and is in an downward trend. Volatility is relatively normal as compared to the average volatility over the last 10 periods. Our volume indicators reflect moderate flows of volume into USRM.PK (mildly bullish). Our trend forecasting oscillators are currently bearish on USRM.PK and have had this outlook for the last 22 periods.

Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.

Stochastic Oscillator

One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 56.7031. This is not an overbought or oversold reading. The last signal was a buy 26 period(s) ago.

Relative Strength Index (RSI)

The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 64.84. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a sell 36 period(s) ago.

Commodity Channel Index (CCI)

The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is 269.This is an overbought reading. However, a signal isnt generated until the indicator crosses below 100. The last signal was a sell 2 period(s) ago.

MACD

The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a buy 13 period(s) ago.

cell, heffx, highlights, MKTS, otc, stem, stock, US, USRM

John Heffernan is a Junior Analyst at HEFFX. John is studying Economics and is a contributor on equities at Live Trading News.

Read the original post:
US Stem Cell Inc (OTCMKTS:USRM) HEFFX Highlights - Live Trading News

Stem cell agency’s response to questions about its performance … – Capitol Weekly

News

by DAVID JENSEN posted 05.23.2017

Eds Note: Here is the full text of the response from the California stem cell agency to a query about the five most important things that it thinks Californians should know about the $3 billion effort. The information was provided by Kevin McCormack, senior director for communications at the agency.

Its hard to limit it to 5 because we have done so many different things that, in their own way, are pioneering and ground-breaking. Its like asking someone to choose their favorite child. We love them all equally.

1) Research we have supported has cured more than 30 children of a fatal rare immune disorder. That same approach has also cured a young man of another rare immune disorder and is now being used to help find a cure for sickle cell anemia a condition that affects more than 100,000 people in the US, most of them African Americans

2) We have funded 29 projects in clinical trials for a variety of diseases including heart disease, cancer, diabetes, HIV/AIDS, spinal cord injuries and the leading cause of vision loss and blindness in the US

3) We are focused on adding another 40 new clinical trials by 2020, including rare diseases and those affecting children

4) We place patients at the heart of everything we do and every decision we make. Nothing gets done at CIRM, including what we fund and how clinical trials are designed, without the input of patients and patient advocates. They know best what needs to be done and their voices are essential in making decisions about treatments that could change their lives, even save their lives

5) CIRM has made California a world leaders in stem cell research, attracting some of the most talented scientists to the state to develop new treatments and funding world-class research facilities in which the research is conducted free from federal restrictions

6) We have created the CIRM Alpha Stem Cell Clinic Network and the Stem Cell Center, two unique institutions that combined can improve the ability of researchers to get their products approved for clinical trials, and to increase the chances those clinical trials will be successful. These are already attracting both CIRM and non-CIRM funded projects to California, and will be an enduring contribution to the development of stem cell projects of all kinds.

In addition we created the iPSC Bank which is developing a repository of more than 3,000 different cell types for research into the causes, and potential treatments for diseases as varied as Alzheimers and autism, heart disease and vision loss.

We are helping create new jobs and generate new taxes. A 2014 economic impact report showed that by that year alone we had generated $284 million in new taxes for the state and helped create 38,000 new job years (thats economist speak for 38,000 jobs that last one year, 19,000 that last two, etc.)

We changed the way our Board votes to ensure there would be no more concerns about the perception of conflict of interest. By preventing heads of institutions who could receive stem cell funds from voting on any funding issue, we took that off the table so that we can focus on our main goal, helping patients.

We have created leadership and trainee programs such as our Bridges program that are helping train the next generation of stem cell scientists.

We played a key role in advancing the 21st Century Cures Act and that two of the first projects approved for accelerated review and approval are CIRM-funded clinical trials. Humacyte was the very first project granted Regenerative Medicine Advanced Therapy and last week jCyte was granted RMAT designation for its work in treating retinitis pigmentosa (heres a fabulous blog about that).

Dont forget, we have around $650 million left to spend, thats far more than any other state has available (New York, for example has $50m a year, Connecticut just $10m ) and more than many countries, and we intend to use that money to continue to accelerate the research that will provide new treatments and cures.

Support for Capitol Weekly is Provided by:

Read more:
Stem cell agency's response to questions about its performance ... - Capitol Weekly

Scientists just created the world’s first lab-grown human blood stem cells – Yahoo News

In a breakthrough of potentially enormous importance, researchers have grown the stem cells that produce blood inside a lab for the first time. The advance could help pave the way for both the creation of blood for transfusions, as well as for treating patients with blood disorders using their own cells, instead of having to rely on donor marrow transplants.

Bone marrow transplants offer a cure to leukemia, sickle cell disease, and a variety of other blood disorders, Dr. Raphael Lis, from Weill Cornell Medical College in New York, told Digital Trends. The problem is that many patients dont have a well-matched donor to provide the marrow needed to reconstitute their blood with healthy cells. To address this challenge, we and others have been trying to develop reliable, lab-based methods to generate the essential blood-producing component of bone marrow: Hematopoietic stem cells.

To make their blood stem cells, the Weill Cornell researchers took cells from the walls of animal lungs, and then used aset of four proteins they had identified that encouraged them to form blood stem cells. In an experiment, the reprogrammed blood stem cells were shown to regenerate the entire blood system of mice for the duration of their lifespan, as well as providing a boost to theirimmune systems.

The results demonstrate a proof-of-concept for efficiently converting the cells that line blood vessels into fully-functioning stem cells, which can be transplanted to provide a lifetime supply of new and healthy blood cells.

We are now testing our method in large animals, Lis continued. We devised a new nonintegrative approach we are currently testing in monkeys in collaboration with the Fred Hutchinson Institute.Providing that these monkeys show positive results and no sign of hematologic malignancies, Lis said that this would allow us to push this method one step close to translation to clinic.

Lis team isnt the only one to experience a breakthrough in this area. Another newly published study coming out of Harvard Medical School started withhuman pluripotent stem cells, referring to stem cells capable of turning into any other type of cell in the human body. They then applied proteins which they discovered triggered the pluripotent cells to transform into blood stem cells. In tests also involving mice, these produced new red and white blood cells, in addition to platelets.

Taken together, the two projects represent a significant advance. You can read more about the Weill Cornell Medical College study here, and the Harvard Medical School study here.

Visit link:
Scientists just created the world's first lab-grown human blood stem cells - Yahoo News

Rosario: Once a migrant worker, he’s revolutionizing brain surgery, cancer fight – TwinCities.com-Pioneer Press

Dr. Qs eyes widen and the hands that once picked grapes and now perform surgeries spring into action. He explains in laymans terms how he and a plastic surgeon teamed up to perform anterior brain tumor removals through an incision on the eyelid.

The way traditional surgery has been done is to remove the scalp forward, and then you do the removal of the bone, and then you take the tumor out, Dr. Alfredo Quiones-Hinojosa explained during a chat Thursday at a hotel in downtown Rochester, Minn.

Now, he explained, the plastic surgeon teammate makes the same incision used for movie stars when their eyelids get droopy. And tumors as large as three centimeters have been excised through this eyebrow-raising technique.

The method reduces, if not eliminates, cranial trauma and retraction of the brain. He has done 60 to 70 such operations in the past five years.

Supremely impressive. The same could be said of Quiones-Hinojosa, who now serves as chair of Neurologic Surgery at the Mayo Clinic complex in Jacksonville, Fla. Colleagues tagged him with that catchy Dr. Q monikeryears ago.

On New Years Day 1987, Quiones-Hinojosa, in pursuit of a dream he felt he could not realize in his native Mexico, scaled an 18-foot barbed wire fence at the U.S.-Mexico border.He was 19.

He began work picking grapes, cotton, cantaloupe, tomatoes and other crops. Twelve years later, he graduated with honors from Harvard Medical School.

Hard work, resiliency, perseverance, never giving up on your dreams are the same principles then that keep me going today as a brain surgeon, scientist, professor, philanthropist and entrepreneur, he said.

As a migrant worker, I worked with my hands and brains, he added. The difference is that the stakes are much higher, because back then I only had my life in my hands. I now have the lives of patients in my hands

The oldest of six children, the 49-year old father of three grew up dirt poor in a small village outside Mexicali in Baja California. The family plunged into further poverty after his father lost his gas station.

Alfredo went to school barefoot at times.

Wanting to help his family, Quiones-Hinojosa was barely 15 when he went to work for an uncle at a migrant farm in Mendota, Calif. He spent the summer months weeding fields and picking cotton and produce. He would return home to Mexico with $1,000, most of which he gave to his parents to make ends meet.

He obtained a teaching license when he was 19 years old. But he had a dream of becoming a doctor a goal inspired by his maternal grandmother, a curandera, Spanish for village healer. He realized America gave him the better shot to achieve it.

Border agents had confiscated his Mexican passport at a checkpoint after learning that he had illegally worked in the U.S. with only a tourist visa.

As he described in his memoir, Becoming Dr. Q: My Journey from Migrant Farm Worker to Brain Surgeon (University of California Press, 2011), Quiones-Hinojosa scaled the fence separating Mexicali from Calexico, Calif. But he was caught by border agents and sent back.

He waited a few hours and climbed over the fence again. A cousin drove him to San Diego, where he bought an airline ticket to Los Angeles with no ID.

It was very different then, he recalled.

Broke and unable to speak a word of English, he slept inside the terminal and ate food travelers had left on tables until another cousin showed up two days later for the ride to the farms in Mendota.

Quiones-Hinojosa worked as a migrant for two years and then landed a job as a welder and cleaner with a railroad company. He nearly lost his life at age 21 when he fell 18 feet into a railroad tanker and was overcome by petroleum fumes. He was pulled up barely conscious and taken to a nearby hospital.

He juggled work and studies at a community college while homeless and living in a small camper trailer with a leaky roof. There were days he woke up drenched.

We are equipping (stem cells body fat), training them, arming them with special tools so we can put them back in humans and fight all kinds of cancer.

At the urging of a friend, Quiones-Hinojosa applied to the University of California at Berkeley. He was accepted. With the help of a scholarship, hemajored in psychology and took several calculus, physics and chemistry classes to boost his grade-point average.

He wrote an honors thesis on neuroscience and was accepted to Harvard Medical School. He married and became a U.S. citizen during his time there. He graduated with honors in 1999 and was the class valedictorian.

He had long resisted the naysayers, the ones who would say Youre not Mexican. You are too smart, or even friends who told him that schools like Harvard were only for the elite, not for Mexican migrant and manual laborers like him. His dream would not let him quit.

Following a residency in San Francisco, Quiones-Hinojosa joined the staff at Johns Hopkins in Baltimore in 2005 as a professor of neurological surgery and oncology. He has served as director of both the brain tumor surgery and pituitary surgery programs at the medical center. And he has authored several textbooks on stem-cell biology and neurosurgical techniques.

Quiones-Hinojosa joined the Mayo team eight months ago, where he teaches and also heads a team of scientists working on a potentially promising way fight to fight cancer: stem cells extracted from a persons fat.

We are equipping them, training them, arming them with special tools so we can put them back in humans and fight all kinds of cancer, said Quiones-Hinojosa, who came to Minnesota this past week to make a presentation on the research.

Lab results, in which human cancer cells have been injected into animals and then treated with the fat cells, have been unbelievably positive. We have cured cancer in animals, he said.

He believes it will take another two or three years before the procedure may be done on a human patient at the Mayo Clinic.

Quiones-Hinojosa acknowledges that individuals and groups have pressured him to speak out on the immigration debate.

I always tell people that these are complex issues, he said. I am not an expert on immigration. I know about cancer. I know about brain surgery. I know about cell migration. My responsibility is not so much to talk about immigration but to serve as a role model for all those people who have come to this country with a dream to make this world a better place.

A movie production company headed by Brad Pitt is working on a movie based on his life. The script is scheduled to be completed by this summer. Casting will follow.

I ask Quiones-Hinojosa if he would like Brad Pitt to play him.

No, he chuckled. Hes too good-looking.

Continue reading here:
Rosario: Once a migrant worker, he's revolutionizing brain surgery, cancer fight - TwinCities.com-Pioneer Press

Asymmetrex Named One of the "50 Most Valuable Brands of the Year 2017" by The Silicon Review – Benzinga

Yesterday, when Silicon Valley magazine The Silicon Review announced its 2017 class of 50 Most Valuable Brands, one member, private stem cell biotechnology start-up Asymmetrex, may have seemed an unusual selection. However, the company's unique in silico approach to counting therapeutic tissue stem cells earned it this recognition.

Boston, MA (PRWEB) May 18, 2017

When James Sherley, was notified earlier this year that his company Asymmetrex had been selected as one of the 50 Most Valuable Brands for the Year 2017 by The Silicon Review, he was not surprised as others might be. Sherley says, "I felt like we had been making good progress increasing Asymmetrex's value, but this recognition by Silicon Valley was particularly meaningful. Our selection by The Silicon Review may seem odd to some, but it makes perfect sense to us. We are able to count adult tissue stem cells for the first time, how? By adapting and designing in silico computational simulation techniques to reveal previously unmeasured properties of adult tissue stem cells, like for instance their number!"

Sherley had a theoretical concept for counting tissue stem cells since before he and his collaborators published a 2001 seminal report explaining how the culture of human tissue cells depends on the unique cell production abilities of tissue stem cells. However, implementing and testing his concept would require enlisting computational modeling expertise. Although Sherley was a professor at MIT, during his time there from 1998 to 2007, he was able to entice only one computer science graduate student to work with him on the idea as a half-semester interdisciplinary experience project.

Then Sherley met Frank Abdi, Ph.D. at a biology-mesomechanics integrative conference in Vicenza, Italy in 2011. Abdi is the founder and chief scientist at AlphaSTAR Corporation, a leading global consulting company in the aircraft and aerospace industry. In AlphaSTAR, Abdi had developed an award-winning, proprietary suite of statistical computational software for simulating the complex behavior of composite materials in high mechanical stress crafts like airplanes, racing cars, and space shuttles. Abdi had a long-standing interest in applying these malleable computational tools to problems in medicine. So, it did not take long for Abdi and Sherley to recognize that they were the ideal team to advance Sherley's computational tissue stem cell counting concept to practical use.

With other AlphaSTAR staff, the two began by translating Sherley's biological models into computational code. When Asymmetrex was formed in 2013, the two companies added staff and resources to accelerate their efforts to develop and validate the new counting approach. By the middle of 2016, they had completed development of the AlphaSTEM Test, a working software program validated for counting tissue stem cells in human lung, bone marrow, liver, and amniotic fluid, as well as for detecting tissue stem cell-active compounds like drug candidates. The data input required for the AlphaSTEM Test is easily obtained total cell count data from serial culture of dissociated human tissue cells.

Asymmetrex now markets the AlphaSTEM Test with the computing support of AlphaSTAR. Before the AlphaSTEM Test, there was no method available for counting adult tissue stem cells specifically. Now, it is possible to count tissue stem cells in experiments in research labs; to determine the dose of stem cells in approved stem cell therapies; to determine the quality and dose of stem cells used in private stem cell clinic treatments; to determine stem cell dose for better interpretation of stem cell clinical trial results; to monitor and optimize biomanufacturing processes for therapeutic tissue stem cells; to determine the dose of genetically-engineered stem cells in gene and gene editing therapies; to have earlier screening for stem cell-toxic drugs that fail in clinical trials because of chronic organ failure; to identify environmental toxicants that alter tissue stem cells; and to identify compounds that improve health by positive effects on tissue stem cells.

The many benefits that will flow from now being able to address these many waiting unmet needs and markets are the basis for The Silicon Review's recognition of Asymmetrex's high value in 2017 and beyond.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex's founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company's patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex's focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/05/prweb14347779.htm

See the original post:
Asymmetrex Named One of the "50 Most Valuable Brands of the Year 2017" by The Silicon Review - Benzinga

Lab-Grown Blood Stem Cells Produced at Last – Scientific American

After 20 years of trying, scientists have transformed mature cells into primordial blood cells that regenerate themselves and the components of blood. The work, described today inNature, offers hope to people with leukaemia and other blood disorders who need bone-marrow transplants but cant find a compatible donor. If the findings translate into the clinic, these patients could receive lab-grown versions of their own healthy cells.

One team, led by stem-cell biologist George Daley of Boston Childrens Hospital in Massachusetts, created human cells that act like blood stem cells, although they are not identical to those found in nature. A second team, led by stem-cell biologist Shahin Rafii of Weill Cornell Medical College in New York City, turned mature cells from mice into fully fledged blood stem cells.

For many years, people have figured outparts of this recipe, but theyve never quite gotten there, says Mick Bhatia, a stem-cell researcher at McMaster University in Hamilton, Canada, who was not involved with either study. This is the first time researchers have checked all the boxes and made blood stem cells.

Daleys team chose skin cells and other cells taken from adults as their starting material. Using a standard method, they reprogrammed the cells intoinduced pluripotent stem (iPS) cells, which are capable of producing manyother cell types. Until now, however, iPS cells have not been morphed into cells that create blood.

The next step was the novel one: Daley and his colleagues inserted seven transcription factorsgenes that control other genesinto the genomes of the iPS cells. Then they injected these modified human cells into mice to develop. Twelve weeks later, the iPS cells had transformed into progenitor cells capable of making the range of cells found in human blood, including immune cells. The progenitor cells are tantalizingly close to naturally occurring haemopoetic blood stem cells, says Daley.

Bhatia agrees. Its pretty convincing that George has figured out how to cook up human haemopoetic stem cells, he says. That is the holy grail.

By contrast, Rafiis team generated true blood stem cells from mice without the intermediate step of creating iPS cells. The researchers began by extracting cells from the lining of blood vessels in mature mice. They then inserted four transcription factors into the genomes of these cells, and kept them in Petri dishes designed to mimic the environment inside human blood vessels. There, the cells morphed into blood stem cells and multiplied.

When the researchers injected these stem cells into mice that had been treated with radiation to kill most of their blood and immune cells, the animals recovered. The stem cells regenerated the blood, including immune cells, and the mice went on to live a full lifemore than 1.5 years in the lab.

Because he bypassed the iPS-cell stage, Rafii compares his approach to a direct aeroplane flight, and Daleys procedure to a flight that takes a detour to the Moon before reaching its final destination. Using the most efficient method to generate stem cells matters, he adds, because every time a gene is added to a batch of cells, a large portion of the batch fails to incorporate it and must be thrown out. There is also a risk that some cells will mutate after they are modified in the lab, and could form tumours if they are implanted into people.

But Daley and other researchers are confident that the method he used can be made more efficient, and less likely to spur tumour growth and other abnormalities in modified cells. One possibility is to temporarily alter gene expression in iPS cells, rather than permanently insert genes that encode transcription factors, says Jeanne Loring, a stem-cell researcher at the Scripps Research Institute in La Jolla, California. She notes that iPS cells can be generated from skin and other tissue that is easy to access, whereas Rafiis method begins with cells that line blood vessels, which are more difficult to gather and to keep alive in the lab.

Time will determine which approach succeeds. But the latest advances have buoyed the spirits of researchers who have been frustrated by their inability to generate blood stem cells from iPS cells. A lot of people have become jaded, saying that these cells dont exist in nature and you cant just push them into becoming anything else, Bhatia says. I hoped the critics were wrong, and now I know they were.

This article is reproduced with permission and wasfirst publishedon May 17, 2017.

Continue reading here:
Lab-Grown Blood Stem Cells Produced at Last - Scientific American

Stem Cell Regeneration Clinics: Waiting to Pounce on the Desperate – Patheos (blog)

Manuelas most recent email set my skeptic senses tingling. This worried Colombian wife had reached out to me across the transom of the World Wide Web emphasis on the World Wide because of my personal experience and extensive research into awareness in vegetative states. Yet in this instance, I think my skeptical chops may be more helpful, as I attempt to get between her and predatory stem cell regeneration quacks.

Youll see why Im so concerned when you read her message:

Thanks for replying to my emails, this also helps me a lot [after I sent her a list Kate Allatt prepared for people in a locked-in or minimally conscious state].

I think my Husband (His name is Felipe [my pseudonym for him])is in that period of the coma [referring to my last email, in which I described my partial awareness during my coma, as my consciousness flickered in and out], he seem to be conscious some times, but other times he looks like he is somewhere else. He also has against his health that he has lost so much weight, he was 185 pounds, and today he is 125. We are looking for other options too, there is something called cells regeneration, it is very expensive, but I think is a good option. I will check out your blog.

Have a great day!

You may have picked this up by now, but my diplomacy skills are so atrocious that I could qualify for a position in the Trump administration diplomatic corps if I werent such a liberal. Thus, this was my typically too-blunt reply:

Manuela,

I would highly recommend against trying stem cell regeneration! Its not only unproven, but is potentially extremely dangerous. Read this article about three women who lost their all or part of their sight after having stem cells injected in their eyes in an attempt to cure macular degeneration:Patients Lose Sight After Stem Cells Are Injected Into Their Eyes. I think that in many cases, stem cell regeneration therapy is performed by quacks or at least unlicensed doctors pushing an unproven therapy, often exploiting desperate people.

If I were you, I would first try Ambien. Its harmless, inexpensive to try, and has had a few but remarkable successes (it was a small study). Zolpidem is the drugs name. Its available in a cheap generic. I used to take it myself before my coma.

Another technique that has shown temporary effectiveness is deep brain stimulation. I put some links into my first email, but here they are again (actually, this time the Ambien link is more specific to the drug treatment). Ambien:Sleeping pill may rouse coma patientsand deep brain stimulation:Electric brain stimulation rouses some people in a minimally conscious or vegetative state. The other thing that might help Felipes would be the physical therapy youve already said you were committed to beginning. If careful enough, that should be harmless as well.

As for Felipes weight, I myself lost a lot of weight and became dangerously skinny while being fed through my gastric tube. Perhaps you can request the high calorie liquid food I was eventually put on (if he isnt on it already).

Also, would you like me to put you in contact with the woman I mentioned who was in a locked-in state, Kate Allatt? (The link is Kates website, so you can contact her yourself if you like.) Kate is much more experienced in directing patients to resources than I am! In her memoir, by the way, she advocates for sometimes going against doctors wishes when you know whats best for your own body. She wasnt talking about a loved ones body, but you are Felipes voice right now.

At any rate, I hope you have a great day, as well, and that Felipe continues to improve!

There are further medical steps Manuela could take beyond the ones I had already suggested to her, though some involve slightly more powerful drugs. (Shes a looong way away from worrying about Ambien affecting Felipes driving.) These drugs at least have the advantage of having shown clinical effectiveness, albeit in studies that were small by necessity.

While stem cell regeneration is a promising area of legitimate medical research, these unlicensed clinics are a whole other kettle of fishiness. I had read about these scammers before, including an article about threewomen who lost their eyesight in whole or in part in an attempt to forestall their macular degeneration (which I linked to in my email).

I had also read about the sad case of Jim Gass, who had traveled to Mexico, China, and Argentina and paid tens of thousands of dollars to have stem cells injected into his spine in order to help him recover from a stroke.

Instead, he developed a huge tumor on his spine.

Whereas Gass was hampered before with a disabled arm and weakness in one of his legs, hes now a quadriplegic with the exception of one arm. And the growth of his spinal tumor continues unabated.

It may be too late for Jim Gass to learn this lesson about the dangers of unlicensed and unregulated stem cell regeneration clinics. But how can I impress that on Manuela without sounding paternalistic?

On the one hand, shes obviously a dogged online researcher. Thats how she found my coma recovery blog in the first place. But theres a reason why these scammers have a continual stream of victims beating down their doors to be fleeced.

There are a lot of desperate patients out there with no legitimate medical treatments, and theyre grasping for treatment options. Ive only been able to sense secondhand what my loved ones went through as I lay near death, with my doctors telling them to give up hope for my full recovery.

Or any recovery at all.

Keith did what Manuela is doing now, researching online. He found Dr. Adrian Owens tennis study, in which Dr. Owen and his team managed to communicated with a few people judged to be in persistent vegetative states.

That gave Keith the encouragement to continue trying to stimulate my mind as best he could without access to the expensive fMRI scanners Dr. Owen et al used.

What kind of desperately-needed hope can I offer Manuela?

Well, Ill probably send her a few more links to clinically tested treatments. Amantadine,a flu-fighting medication used as well for tremor in Parkinsons patients, and Levadopa(also used for Parkinsons disease) have both helped to improve awareness, increase periods of wakefulness, or even sparked awakening. While use of these drugs would be off label, at least there is clinical if limited data to back up their potential effectiveness.

Indeed, this is what the International Brain Injury Association had to say regarding patients in developing countries:

The situation gets worse in undeveloped countries where one can hardly find a brain trauma neurorehabilitation unit and exceptionally few patients can access them.

These treatment studies of course need to be replicated to spread more widely. But given that they employ tested treatments/drugs that are being used off label by specialists in the developed world, theyre certainly safer than stem cell regeneration, which is at best worthless and at worst has caused proven harm to many.

Manuela is already determined to take the matters into her own hands by giving Felipe physical therapy, despite his doctors dismissal of its utility. (My doctors said the same thing, and I believe that passive exercise wouldve at the very least shortened my recovery time. And given that my awareness and movement improved every time I was significantly stimulated, the physical therapy might well have hastened my awakening.)

In the end, all I can do is to try to gently encourage Manuela to try these safer and much cheaper interventions, which have show actual clinical effectiveness. With my decided lack of diplomatic skill, Im far from the best person to attempt this.

The stem cell regeneration clinic scammers will be waiting to pounce if I fail.

For as little as $1 a month, you can help feed a starving writer. Please considersupporting my work on Patreon.

See original here:
Stem Cell Regeneration Clinics: Waiting to Pounce on the Desperate - Patheos (blog)